Verisante Technology Inc. | Balance Sheet

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
Cash & Short Term Investments
455.40
339.60
-
11.40
Total Accounts Receivable
279.70
62.60
19.20
7.10
Inventories
857.10
1,049.90
981.80
946.80
Other Current Assets
58.10
253.70
231.90
225.60
Total Current Assets
1,650.30
1,705.80
1,232.90
1,190.90
Net Property, Plant & Equipment
105.30
24.40
2.30
0.70
Intangible Assets
3,683.30
2,988.20
2,133.20
1,137.50
Total Assets
5,438.90
4,718.40
3,368.50
2,329.10
ST Debt & Current Portion LT Debt
-
-
152.00
320.60
Accounts Payable
686.40
1,275.90
945.40
1,284.00
Other Current Liabilities
-
275.70
414.40
398.70
Total Current Liabilities
686.40
1,551.60
1,511.80
2,003.30
Other Liabilities
-
-
577.10
577.10
Total Liabilities
686.40
1,551.60
2,088.90
2,580.30
Common Equity (Total)
4,752.50
3,166.80
1,279.60
251.30
Total Shareholders' Equity
4,752.50
3,166.80
1,279.60
251.30
Total Equity
4,752.50
3,166.80
1,279.60
251.30
Liabilities & Shareholders' Equity
5,438.90
4,718.40
3,368.50
2,329.10

About Verisante Technology

View Profile
Address
2639 Viking Way
Richmond British Columbia V6V 3B7
Canada
Employees -
Website http://www.verisante.com
Updated 07/08/2019
Verisante Technology, Inc. a medical device company, which is engaged in development, regulatory, production and commercialization of skin cancer detection systems. Its products include Verisante Aura and Verisante Core. The Verisante Aura is a multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer.